ObsEva SA: ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

-Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3 PRIMROSE

Related Keywords

Switzerland ,Geneva ,Genè ,Sweden ,Japan ,United States ,Stockholm ,Japanese ,Swiss ,Jacques Donnez ,Joyce Allaire ,Hugh Taylor ,Exchange Commission ,Energyx Ray Absorptiometry ,Program In Uterine Fibroids ,Society Of Endometriosis ,Swiss Exchange ,Week Data ,Switzerland December ,Uterine Disorders ,Term Efficacy ,Heavy Menstrual Bleeding ,Uterine Fibroids ,Week Results ,Two Placebo Controlled ,Term Safety ,Bone Mineral Density ,Long Term Treatment ,Dose Ranging Trial ,Dual Energyx Ray Absorptiometry ,Nasdaq Global Select Market ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,Obseva ,Costs ,Symposium ,Presents ,Linical ,Data ,Mural ,Snrh ,Antagonist ,Linzagolix ,Feud ,Congress ,021 ,